SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

NBIP-1968

NBIX·NEUROCRINE BIOSCIENCES INC
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
Years away, if successful. The drug is in Phase 1 safety testing with no disclosed completion timeline. Typical obesity drug development from Phase 1 to FDA approval takes 5-8 years.
Why 2/10
No hard, dated catalyst is scheduled for NBIP-1968 in the next ~12 months. The Phase 1 first-in-human study began in August 2026 with no disclosed completion date or data-readout timeline. As an early-stage asset at a diversified company with multiple approved products, even a data event would have limited stock impact.
Actionable Insight NEUTRAL

NBIP-1968 is too early-stage (Phase 1, initiated August 2026) to drive a near-term share-price move for NBIX. Watch for Phase 1 safety/tolerability data readouts, but no specific date has been disclosed. The more relevant catalysts for NBIX in the next 12 months are commercial execution of its approved products (INGREZZA, CRENESSITY, VYKAT XR) and any pipeline updates from its more advanced neurology/psychiatry programs.

Price Chart

Loading chart...

Executive Summary

NBIP-1968 is Neurocrine Biosciences' investigational GLP-1/GIP/glucagon receptor triple agonist for obesity, currently in a Phase 1 first-in-human study that began in August 2026. It is designed as a once-weekly injection and intended for fixed-dose combination with Neurocrine's other Phase 1 asset NBIP-2118 (a CRF2 receptor agonist aimed at muscle preservation). The drug enters a highly competitive obesity market where Eli Lilly's retatrutide (same triple-agonist mechanism) is already in Phase 3 with strong weight-loss data. Neurocrine is a well-capitalized, diversified biotech with approximately $1.1B in quarterly revenue from three approved products (INGREZZA, CRENESSITY, VYKAT XR), making NBIP-1968 a small, early-stage pipeline component with no near-term binary catalyst for the stock.

How It Works

NBIP-1968 is a triple agonist, meaning it activates three different hormone receptors at once: GLP-1, GIP, and glucagon. GLP-1 and GIP are natural hormones that help control blood sugar and reduce appetite (similar to how popular weight-loss drugs like Wegovy/Ozempic work). Adding glucagon receptor activation is intended to increase energy burning. The drug is designed as a once-weekly injection and is meant to be combined with another Neurocrine drug (NBIP-2118) that targets a different pathway to preserve muscle mass during weight loss.

Trial Status

A Phase 1 first-in-human study was initiated on August 7, 2026, evaluating single ascending doses of NBIP-1968 for safety and tolerability in adults across BMI categories including overweight and obese. No data readout date has been disclosed.

The Two-Sided Case

▲ Bull Case4
Neurocrine has a strong track record of drug development and commercialization, with three approved products generating over $1.1B in quarterly revenue, providing ample resources to fund the obesity pipeline.
NBIP-1968 is designed for fixed-dose combination with Neurocrine's proprietary CRF2 agonist NBIP-2118, potentially offering a differentiated muscle-sparing weight-loss profile versus existing incretins.
The global obesity drug market is projected to be worth tens of billions annually, so even a modest share could represent significant upside if NBIP-1968 eventually succeeds through Phase 2/3.
Neurocrine's internal discovery of NBIP-1968 suggests the company has built proprietary peptide-engineering capabilities that could extend beyond this single candidate.
▼ Bear Case4
NBIP-1968 is a 'me-too' triple agonist entering a field already dominated by Eli Lilly's retatrutide, which is in Phase 3 with 28.7% mean weight loss data and head-to-head wins against Ozempic. Neurocrine is years behind.
The Phase 1 trial only evaluates single ascending doses for safety/tolerability; no efficacy data or weight-loss numbers have been disclosed, making differentiation from competitors impossible to assess.
Obesity is an intensely competitive space with Novo Nordisk, Eli Lilly, and dozens of other biotechs. A Phase 1 entrant with no clear differentiation faces high clinical and commercial risk.
NBIP-1968 is a very small part of Neurocrine's overall value. The company's ~$1.1B quarterly revenue comes from approved neurology drugs (INGREZZA, CRENESSITY, VYKAT XR), so even positive Phase 1 data would have limited impact on the stock.

Upcoming Catalysts

  • Phase 1 safety/tolerability data readout (date not yet disclosed)
  • Potential progression to multiple-ascending-dose portion of Phase 1
  • Any future combination study with NBIP-2118

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report

Sources · 7

Hover a chip for the title
1 prnewswire.com2 prnewswire.com3 investor.lilly.com4 reuters.com5 neurocrine.com6 neurocrine.com7 novapharmanews.com